• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较不同非侵入性方法评估姜黄素对非酒精性脂肪性肝病患者肝纤维化的影响。

Comparing different non-invasive methods in assessment of the effects of curcumin on hepatic fibrosis in patients with non-alcoholic fatty liver disease.

作者信息

Saadati Saeede, Hekmatdoost Azita, Hatami Behzad, Mansour Asieh, Zahra Zahra, Hedayati Mehdi, Sadeghi Amir

机构信息

Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Gastroenterol Hepatol Bed Bench. 2018 Winter;11(Suppl 1):S8-S13.

PMID:30774801
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6347983/
Abstract

AIM

The aim of this study was to examine the effects of curcumin supplementation on hepatic fibrosis using different fibrosis assessment methods.

BACKGROUND

Nonalcoholic fatty liver disease (NAFLD) may progress to hepatic fibrosis. Detection of hepatic fibrosis should be measured by liver biopsy, which is an invasive method. Thus, some non-invasive methods are suggested.

METHODS

Hepatic fibrosis was evaluated in forty six patients with NAFLD before and three months after supplementation with 1.5 gram curcumin or placebo. Methods of assessments included fibroscan, and calculating non-invasive marker panel including FIB-4 (Fibrosis4), NFS (NAFLD fibrosis score), APRI (AST (Aspartate aminotransferase) Platelet Ratio Index), and BARD (body mass index, AST/ALT (Alanine aminotransferase ratio, diabetes).

RESULTS

Fibrosis score was reduced significantly after curcumin supplementation using fibroscan (p<0.01), FIB-4 (p<0.05) and APRI (p<0.05) tests, while fibrosis score did not change significantly using BARD and NFS methods (p>0.05).

CONCLUSION

Our results revealed that fibroscan, FIB-4, and APRI are similar in assessment of hepatic fibrosis changes after curcumin supplementation. Future studies with higher sample sizes are needed to confirm these results.

摘要

目的

本研究旨在使用不同的纤维化评估方法来检测姜黄素补充剂对肝纤维化的影响。

背景

非酒精性脂肪性肝病(NAFLD)可能会发展为肝纤维化。肝纤维化的检测通常采用肝活检,但这是一种侵入性方法。因此,有人提出了一些非侵入性方法。

方法

对46例NAFLD患者在补充1.5克姜黄素或安慰剂之前及之后三个月进行肝纤维化评估。评估方法包括FibroScan检查,以及计算非侵入性标志物组合,包括FIB-4(纤维化4项)、NFS(NAFLD纤维化评分)、APRI(天冬氨酸氨基转移酶与血小板比值指数)和BARD(体重指数、AST/ALT(丙氨酸氨基转移酶比值)、糖尿病)。

结果

使用FibroScan检查(p<0.01)、FIB-4(p<0.05)和APRI(p<0.05)检测时,补充姜黄素后纤维化评分显著降低,而使用BARD和NFS方法时纤维化评分无显著变化(p>0.05)。

结论

我们的结果显示,FibroScan检查、FIB-4和APRI在评估补充姜黄素后的肝纤维化变化方面具有相似性。需要进一步开展更大样本量的研究来证实这些结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11e4/6347983/809d457cca0b/GHFBB-11-S008-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11e4/6347983/809d457cca0b/GHFBB-11-S008-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11e4/6347983/809d457cca0b/GHFBB-11-S008-g001.jpg

相似文献

1
Comparing different non-invasive methods in assessment of the effects of curcumin on hepatic fibrosis in patients with non-alcoholic fatty liver disease.比较不同非侵入性方法评估姜黄素对非酒精性脂肪性肝病患者肝纤维化的影响。
Gastroenterol Hepatol Bed Bench. 2018 Winter;11(Suppl 1):S8-S13.
2
FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.在伊朗班达尔阿巴斯,比较 FIB-4、APRI 和 AST/ALT 比值与 FibroScan 用于评估非酒精性脂肪性肝病患者的肝纤维化。
BMC Gastroenterol. 2021 Dec 3;21(1):453. doi: 10.1186/s12876-021-02038-3.
3
Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.非酒精性脂肪性肝病无创性纤维化工具:APRI、BARD、FIB-4、NAFLD 纤维化评分和 Hepamet 纤维化评分在葡萄牙人群中的验证。
Postgrad Med. 2022 May;134(4):435-440. doi: 10.1080/00325481.2022.2058285. Epub 2022 Mar 30.
4
Diabetes Mellitus Increases the Risk of Significant Hepatic Fibrosis in Patients With Non-alcoholic Fatty Liver Disease.糖尿病增加非酒精性脂肪性肝病患者发生显著肝纤维化的风险。
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):409-416. doi: 10.1016/j.jceh.2021.07.001. Epub 2021 Jul 9.
5
Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.代谢相关脂肪性肝病患者中传统非侵入性纤维化评分系统的验证。
World J Gastroenterol. 2021 Sep 14;27(34):5753-5763. doi: 10.3748/wjg.v27.i34.5753.
6
Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.改良 AST 与血小板比值指数(m APRI)可改善 APRI,更好地预测非酒精性脂肪性肝病患者的肝纤维化及肝硬化。
Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101528. doi: 10.1016/j.clinre.2020.08.006. Epub 2020 Nov 29.
7
Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.无创性纤维化模型诊断准确性:检测纤维化分期变化。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1877-1885.e5. doi: 10.1016/j.cgh.2018.12.031. Epub 2019 Jan 4.
8
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.在退伍军人健康管理局中识别非酒精性脂肪性肝病的肝纤维化程度。
Dig Dis Sci. 2018 Sep;63(9):2259-2266. doi: 10.1007/s10620-018-5123-3. Epub 2018 May 19.
9
Evaluation of Six Noninvasive Methods for the Detection of Fibrosis in Chinese Patients with Obesity and Nonalcoholic Fatty Liver Disease.评估六种无创方法在诊断中国肥胖合并非酒精性脂肪性肝病患者肝纤维化中的价值。
Obes Surg. 2022 Nov;32(11):3619-3626. doi: 10.1007/s11695-022-06251-1. Epub 2022 Sep 7.
10
Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease.在沙特非酒精性脂肪性肝病患者中,Fibroscan与FIB-4、APRI及AST/ALT比值在评估肝纤维化方面的比较
Hepat Mon. 2016 Jul 3;16(7):e38346. doi: 10.5812/hepatmon.38346. eCollection 2016 Jul.

引用本文的文献

1
Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review.评估基于生物活性物质的干预措施对患有代谢功能障碍相关脂肪性肝病(MASLD)的成年人的影响:一项系统综述的结果
Nutrients. 2025 Jan 26;17(3):453. doi: 10.3390/nu17030453.
2
Effects of time restricted feeding combined with Lacto Ovo vegetarian diet on metabolic associated fatty liver disease management: a randomized clinical trial.限时进食联合蛋奶素食对代谢相关脂肪性肝病管理的影响:一项随机临床试验
Sci Rep. 2025 Feb 6;15(1):4463. doi: 10.1038/s41598-025-88773-z.
3
Is Curcumin Intake Really Effective for Chronic Inflammatory Metabolic Disease? A Review of Meta-Analyses of Randomized Controlled Trials.

本文引用的文献

1
Curcumin and Liver Disease: from Chemistry to Medicine.姜黄素与肝脏疾病:从化学到医学
Compr Rev Food Sci Food Saf. 2014 Jan;13(1):62-77. doi: 10.1111/1541-4337.12047.
2
The role of curcumin in liver diseases.姜黄素在肝脏疾病中的作用。
Arch Med Sci. 2019 Oct;15(6):1608-1620. doi: 10.5114/aoms.2018.73596. Epub 2018 Feb 20.
3
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病发病机制的最新研究进展。
姜黄素摄入对慢性炎症代谢性疾病真的有效吗?随机对照试验荟萃分析综述。
Nutrients. 2024 May 31;16(11):1728. doi: 10.3390/nu16111728.
4
Effects of curcumin in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.姜黄素对非酒精性脂肪性肝病患者的影响:一项系统评价和荟萃分析。
Can Liver J. 2024 May 8;7(2):299-315. doi: 10.3138/canlivj-2023-0022. eCollection 2024 May.
5
Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials.姜黄和姜黄素在慢性病防治中的作用:来自临床试验的经验教训。
ACS Pharmacol Transl Sci. 2023 Mar 6;6(4):447-518. doi: 10.1021/acsptsci.2c00012. eCollection 2023 Apr 14.
6
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.基于伊朗和泰国现有证据的姜黄素对代谢功能障碍相关脂肪性肝病影响的更新荟萃分析。
Sci Rep. 2023 Apr 10;13(1):5824. doi: 10.1038/s41598-023-33023-3.
7
Performance of Non-invasive Biomarkers of Liver Fibrosis Amongst Hispanics and African Americans.西班牙裔和非裔美国人中肝纤维化非侵入性生物标志物的表现
Cureus. 2023 Feb 15;15(2):e35032. doi: 10.7759/cureus.35032. eCollection 2023 Feb.
8
Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials.姜黄素补充剂与人类疾病:临床试验的范围综述。
Int J Mol Sci. 2023 Feb 24;24(5):4476. doi: 10.3390/ijms24054476.
9
Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease.姜黄素对非酒精性脂肪性肝病患者的代谢综合征状态无额外获益。
Nutrients. 2022 Aug 6;14(15):3224. doi: 10.3390/nu14153224.
10
The Effect of Curcumin Supplemsentation on Anthropometric Indices in Overweight and Obese Individuals: A Systematic Review of Randomized Controlled Trials.姜黄素补充剂对超重和肥胖个体人体测量指数的影响:系统评价随机对照试验。
Adv Exp Med Biol. 2021;1291:121-137. doi: 10.1007/978-3-030-56153-6_7.
Annu Rev Pathol. 2018 Jan 24;13:321-350. doi: 10.1146/annurev-pathol-020117-043617.
4
A systems biology analysis protein-protein interaction of NASH and IBD based on comprehensive gene information.基于全面基因信息的非酒精性脂肪性肝炎和炎症性肠病蛋白质-蛋白质相互作用的系统生物学分析
Gastroenterol Hepatol Bed Bench. 2017 Summer;10(3):194-201.
5
Curcumin in Hepatobiliary Disease: Pharmacotherapeutic Properties and Emerging Potential Clinical Applications.姜黄素在肝胆疾病中的应用:药物治疗特性及新兴的潜在临床应用
Ann Hepatol. 2017;16(6):835-841. doi: 10.5604/01.3001.0010.5273.
6
Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH.血清生物标志物可预测经活检证实的 NASH 生活方式干预 1 年后肝纤维化的变化。
Liver Int. 2017 Dec;37(12):1887-1896. doi: 10.1111/liv.13480. Epub 2017 Jun 14.
7
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.姜黄素治疗非酒精性脂肪性肝病:一项随机安慰剂对照试验。
Phytother Res. 2016 Sep;30(9):1540-8. doi: 10.1002/ptr.5659. Epub 2016 Jun 8.
8
Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial.姜黄素降低非酒精性脂肪性肝病患者的血脂和尿酸水平:一项随机对照试验。
J Cardiovasc Pharmacol. 2016 Sep;68(3):223-9. doi: 10.1097/FJC.0000000000000406.
9
Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study.FIB-4指数、非酒精性脂肪性肝病纤维化评分和BARD评分预测成年非酒精性脂肪性肝病患者严重纤维化的比较:一项荟萃分析研究。
Hepatol Res. 2016 Aug;46(9):862-70. doi: 10.1111/hepr.12647. Epub 2016 Feb 16.
10
Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.使用非酒精性脂肪性肝病纤维化评分和振动控制瞬时弹性成像对非酒精性脂肪性肝病进行成本效益评估。
Am J Gastroenterol. 2015 Sep;110(9):1298-304. doi: 10.1038/ajg.2015.241. Epub 2015 Aug 25.